Kymera Therapeutics, Inc. (KYMR) is currently Overvalued by 50.69%

Kymera Therapeutics, Inc. (KYMR) appears overvalued by approximately 50.69% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.

Downside (live) 50.69% (from live valuation API)
Confidence (live) 8.5/10 (High conviction overvalued)

Confidence Score is based on the magnitude of upside or downside vs intrinsic value.

Fair value estimate

Unlock fair value

Current price

$114.76

Stock valuation checker

Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.

Explore Our Valuation Calculators

Intrinsic Value Calculator (DCF)ROE Calculator Stock Valuation Calculator

Why is Kymera Therapeutics, Inc. overvalued or undervalued?

Intrinsic value work anchors Kymera Therapeutics, Inc. on owner earnings and balance-sheet capacity; the current quote trades below that anchor, which frames the stock as relatively cheap on a fundamentals-first view.

Versus historical valuation bands, KYMR is closer to the lower end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.

Forward market expectations are muted: the price does not require heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.

Key metrics

P/E ratio: 18.0x
Revenue growth (TTM y/y): 11%
Profit margin: 29.4%
Fair value (model): Unlock

Next steps

Frequently asked questions — KYMR

Is KYMR overvalued right now?

Based on our 2026 models, Kymera Therapeutics, Inc. (KYMR) appears overvalued at $114.76 with roughly 50.7% downside versus fair value. Confirm with valuation ratios and financials before acting.

What is Kymera Therapeutics, Inc.'s intrinsic value?

Our DCF, P/E Multiple, and P/S Multiple models estimate whether KYMR trades above or below fair value. At $114.76, Kymera Therapeutics, Inc. currently looks overvalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.

How is Kymera Therapeutics, Inc.'s intrinsic value calculated?

Tickerplace calculates KYMR's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.

Is KYMR undervalued right now?

A stock is undervalued when price sits below a supportable fair value range. Check whether KYMR's gap aligns with fundamentals using the ratios and financial links on this page.

Peers for KYMR: open their overvalued / undervalued view.

Instant valuation answer